- Home
- GPCR vs PEB Comparison
GPCR vs PEB Comparison
Compare GPCR & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- PEB
- Stock Information
- Founded
- GPCR 2016
- PEB 2009
- Country
- GPCR United States
- PEB United States
- Employees
- GPCR N/A
- PEB N/A
- Industry
- GPCR
- PEB Real Estate Investment Trusts
- Sector
- GPCR
- PEB Real Estate
- Exchange
- GPCR Nasdaq
- PEB Nasdaq
- Market Cap
- GPCR 1.1B
- PEB 1.2B
- IPO Year
- GPCR 2023
- PEB 2009
- Fundamental
- Price
- GPCR $17.59
- PEB $9.71
- Analyst Decision
- GPCR Strong Buy
- PEB Hold
- Analyst Count
- GPCR 7
- PEB 7
- Target Price
- GPCR $76.17
- PEB $11.83
- AVG Volume (30 Days)
- GPCR 734.9K
- PEB 2.3M
- Earning Date
- GPCR 08-11-2025
- PEB 07-29-2025
- Dividend Yield
- GPCR N/A
- PEB 0.40%
- EPS Growth
- GPCR N/A
- PEB N/A
- EPS
- GPCR N/A
- PEB N/A
- Revenue
- GPCR N/A
- PEB $1,469,933,000.00
- Revenue This Year
- GPCR N/A
- PEB $1.70
- Revenue Next Year
- GPCR N/A
- PEB $2.84
- P/E Ratio
- GPCR N/A
- PEB N/A
- Revenue Growth
- GPCR N/A
- PEB 2.00
- 52 Week Low
- GPCR $13.22
- PEB $7.42
- 52 Week High
- GPCR $45.37
- PEB $15.12
- Technical
- Relative Strength Index (RSI)
- GPCR 31.53
- PEB 37.85
- Support Level
- GPCR $17.45
- PEB $10.44
- Resistance Level
- GPCR $18.78
- PEB $11.21
- Average True Range (ATR)
- GPCR 0.82
- PEB 0.41
- MACD
- GPCR 0.00
- PEB -0.13
- Stochastic Oscillator
- GPCR 5.00
- PEB 10.95
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.